1
|
Murakami Y, Nozaki Y, Morosawa M, Toyama M, Ogashiwa H, Ueda T, Nakajima K, Tanaka R, Takesue Y. Difference in the impact of coinfections and secondary infections on antibiotic use in patients hospitalized with COVID-19 between the Omicron-dominant period and the pre-Omicron period. J Infect Chemother 2024:S1341-321X(24)00067-9. [PMID: 38428674 DOI: 10.1016/j.jiac.2024.02.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2024] [Revised: 02/14/2024] [Accepted: 02/26/2024] [Indexed: 03/03/2024]
Abstract
INTRODUCTION This study evaluated the effect of coinfections and/or secondary infections on antibiotic use in patients hospitalized with coronavirus disease 2019 (COVID-19). METHOD Days of therapy per 100 bed days (DOT) in a COVID-19 ward were compared between 2022 (Omicron period) and 2021 (pre-Omicron period). Antibiotics were categorized as antibiotics predominantly used for community-acquired infections (CAIs) and antibiotics predominantly used for health care-associated infections (HAIs). Bacterial and/or fungal infections which were proved or assumed on admission were defined as coinfections. Secondary infections were defined as infections that occurred following COVID-19. RESULTS Patients with COVID-19 during the Omicron period were older and had more comorbidities. Coinfections were more common in the Omicron period than in the pre-Omicron period (44.4% [100/225] versus 0.8% [2/257], respectively, p < 0.001), and the mean DOT of antibiotics for CAIs was significantly increased in the Omicron period (from 3.60 to 17.84, p < 0.001). Secondary infection rate tended to be higher in the Omicron period (p = 0.097). Mean DOT of antibiotics for HAIs were appeared to be lower in the COVID-19 ward than in the general ward (pre-Omicron, 3.33 versus 6.37, respectively; Omicron, 3.84 versus 5.22, respectively). No multidrug-resistant gram-negative organisms were isolated in the COVID-19 ward. CONCLUSION Antibiotic use for CAIs was limited in the pre-Omicron period but increased in the Omicron period because of a high coinfection rate on admission. With the antimicrobial stewardship, excessive use of antibiotics for HAIs was avoided in the COVID-19 ward during both periods.
Collapse
Affiliation(s)
- Yasushi Murakami
- Department of Respiratory Medicine, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Yasuhiro Nozaki
- Department of Respiratory Medicine, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Mika Morosawa
- Department of Respiratory Medicine, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Masanobu Toyama
- Department of Pharmacy, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Hitoshi Ogashiwa
- Department of Clinical Technology, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Takashi Ueda
- Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
| | - Kazuhiko Nakajima
- Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan.
| | - Ryoya Tanaka
- Department of Clinical Infectious Diseases, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, 479-8510, Japan.
| | - Yoshio Takesue
- Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan; Department of Clinical Infectious Diseases, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, 479-8510, Japan.
| |
Collapse
|
2
|
Asaeda T, Ueda T, Nozaki Y, Murakami Y, Morosawa M, Inaba H, Ogashiwa H, Doi M, Nakajima K, Shirakawa M, Nakamura A, Ikeda N, Sugiyama Y, Wada Y, Ito T, Takesue Y. Clinical features of pasteurellosis without an animal bite or scratch in comparison with bite/scratch pasteurellosis. J Infect Chemother 2024:S1341-321X(24)00032-1. [PMID: 38373634 DOI: 10.1016/j.jiac.2024.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2023] [Revised: 12/20/2023] [Accepted: 02/04/2024] [Indexed: 02/21/2024]
Abstract
Pasteurellosis is a common zoonotic infection that occurs after an animal bite or scratch (B/S). We compared the clinical features of six patients with non-B/S pasteurellosis with those of 14 patients with B/S infections. Pasteurella multocida was identified with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in all six non-B/S infections, whereas 13 of the 14 B/S infections were identified with diagnostic kits. The non-B/S infections were pneumonia (n = 3), skin and soft tissue infections (n = 2), and bacteremia (n = 1). Pneumonia occurred in two patients with underlying pulmonary disease, whereas ventilator-associated pneumonia developed in one patient with cerebral infarction. Pasteurella multocida was isolated from a blood specimen and nasal swab from a patient with liver cirrhosis (Child-Pugh class C) and diabetes. Cellulitis developed in one patient with diabetes and normal-pressure hydrocephalus, who had an open wound following a fall, and in one patient with diabetes and a foot ulcer. Three patients with non-B/S infections had no pet and no episode of recent animal contact. The rate of moderate-to-severe comorbidities was significantly higher in patients with non-B/S infections than in those with B/S infections (100% and 14.3%, respectively, p < 0.001). In conclusion, non-B/S infections can develop in patients with chronic pulmonary disease, invasive mechanical ventilation, or open wounds, or who are immunocompromised, irrespective of obvious animal exposure. In contrast to B/S infections, non-B/S pasteurellosis should be considered opportunistic.
Collapse
Affiliation(s)
- Tsubasa Asaeda
- Department of Respiratory Medicine, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Takashi Ueda
- Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan.
| | - Yasuhiro Nozaki
- Department of Respiratory Medicine, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Yasushi Murakami
- Department of Respiratory Medicine, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Mika Morosawa
- Department of Respiratory Medicine, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Hiroko Inaba
- Department of Dermatology, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Hitoshi Ogashiwa
- Department of Clinical Technology, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Miki Doi
- Department of Clinical Technology, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Kazuhiko Nakajima
- Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan.
| | - Manabu Shirakawa
- Department of Neurosurgery, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan.
| | - Akifumi Nakamura
- Division of Thoracic Surgery, Department of Surgery, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan.
| | - Naoto Ikeda
- Division of Hepatobiliary and Pancreatic Diseases, Department of Gastroenterology, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan.
| | - Yuya Sugiyama
- Department of Plastic Surgery, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan.
| | - Yoshihiro Wada
- Department of Dermatology, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan.
| | - Takahiro Ito
- Department of Clinical Infectious Diseases, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, 479-8510, Japan.
| | - Yoshio Takesue
- Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan; Department of Clinical Infectious Diseases, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, 479-8510, Japan.
| |
Collapse
|
3
|
Morioka H, Koizumi Y, Watariguchi T, Oka K, Tomita Y, Kojima Y, Okudaira M, Ito Y, Shimizu J, Watamoto K, Kato H, Nagaoka M, Yokota M, Hasegawa C, Tsuji T, Shimizu S, Ito K, Kawasaki S, Akita K, Kitagawa Y, Mutoh Y, Ishihara M, Iwata S, Nozaki Y, Nozawa M, Kato M, Katayama M, Yagi T. Surgical antimicrobial prophylaxis in Japanese hospitals: Real status and challenges. J Infect Chemother 2024:S1341-321X(24)00023-0. [PMID: 38272262 DOI: 10.1016/j.jiac.2024.01.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Revised: 11/24/2023] [Accepted: 01/18/2024] [Indexed: 01/27/2024]
Abstract
BACKGROUND Information regarding the status of surgical antimicrobial prophylaxis (SAP) in Japanese hospitals is lacking. This study aimed to explore the status of SAP prescriptions for surgeries and adherence to Japanese SAP guidelines. METHODS From February to July 2020, a 1-day multicentre point prevalent survey was conducted at 27 hospitals in Aichi Prefecture, Japan. Patients prescribed SAP were included in this study. The appropriateness of the SAP was evaluated based on the guidelines for selection of antimicrobials and their duration. Surgery was defined as appropriate when all the items were appropriate. RESULTS A total of 728 patients (7.1 %; 728/10,199) received antimicrobials for SAP. Among them, 557 patients (76.5 %, 557/728) underwent the surgeries described in the guidelines. The overall appropriateness of all surgeries was 33.9 % (189/557). The appropriate selection of antimicrobial before/during and after surgery and their durations were 67.5 % (376/557), 67.5 % (376/557), and 43.3 % (241/557), respectively. The overall appropriateness ranged from 0 % (0/37, oral and maxillofacial surgery) to 58.7 % (88/150, orthopaedic surgery) and 27.7 % (36/130, community hospitals with 400-599 beds) to 47.2 % (17/36, specific hospitals). Cefazolin was the most prevalent antimicrobial prescribed before/during (55.5 %, 299/539), and after (45.1 %, 249/552) surgery. In total, 101 oral antimicrobials were prescribed postoperatively. CONCLUSIONS SAP adherence by specific surgical fields and hospitals was shown in this study. Intensive intervention and repeated surveillance are necessary to improve SAP prescriptions in Japanese hospitals.
Collapse
Affiliation(s)
- Hiroshi Morioka
- Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Japan.
| | - Yusuke Koizumi
- Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Nagakute, Japan; Department of Infection Prevention and Control, Wakayama Medical University, Wakayama, Japan
| | | | - Keisuke Oka
- Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Japan; Antimicrobial Stewardship Team, Kariya Toyota General Hospital, Kariya, Japan
| | - Yuka Tomita
- Department of Infectious Diseases, Japanese Red Cross Aichi Medical Centre Nagoya Daini Hospital, Nagoya, Japan
| | - Yumi Kojima
- Infection Control Team, Nagoya Ekisaikai Hospital, Nagoya, Japan
| | | | - Yuji Ito
- Department of Respiratory Medicine, Daiyukai General Hospital, Ichinomiya, Japan
| | - Junichi Shimizu
- Department of Thoracic Oncology, Aichi Cancer Centre Hospital, Nagoya, Japan
| | - Koichi Watamoto
- Department of Hematology, Komaki City Hospital, Komaki, Japan
| | - Hiroki Kato
- Department of Infectious Diseases, Toyota Memorial Hospital, Toyota, Japan
| | | | - Manabu Yokota
- Department of Pharmacy, Handa City Hospital, Handa, Japan
| | - Chihiro Hasegawa
- Department of Infectious Diseases, Nagoya City East Medical Centre, Nagoya, Japan
| | - Takeshi Tsuji
- Department of Pediatrics, Okazaki City Hospital, Okazaki, Japan
| | - Shinsuke Shimizu
- Infection Control Team, Kamiiida Daiichi General Hospital, Nagoya, Japan
| | - Kenta Ito
- Department of General Pediatrics, Aichi Children's Health and Medical Centre, Obu, Japan
| | - Shohei Kawasaki
- Department of Pharmacy, Nishichita General Hospital, Tokai, Japan
| | - Kenji Akita
- Department of Respiratory Medicine, Nagoya City University West Medical Centre, Nagoya, Japan
| | - Yuichi Kitagawa
- Department of Infection Control, National Centre for Geriatrics and Gerontology, Obu, Japan
| | - Yoshikazu Mutoh
- Department of Infectious Diseases, Tosei General Hospital, Seto, Japan
| | | | - Susumu Iwata
- Department of Respiratory Medicine, Kasugai Municipal Hospital, Kasugai, Japan
| | - Yasuhiro Nozaki
- Department of Respiratory Medicine, Tokoname Municipal Hospital, Tokoname, Japan
| | | | - Munehiro Kato
- Department of Respiratory Medicine, Asahi Rosai Hospital, Owariasahi, Japan
| | - Masao Katayama
- Department of Internal Medicine and Rheumatology and Department of Infection Control Team, NHO Nagoya Medical Center, Nagoya, Japan
| | - Tetsuya Yagi
- Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Japan
| |
Collapse
|
4
|
Miyamoto S, Nishiyama T, Ueno A, Park H, Kanno T, Nakamura N, Ozono S, Aihara K, Takahashi K, Tsuchihashi Y, Ishikane M, Arashiro T, Saito S, Ainai A, Hirata Y, Iida S, Katano H, Tobiume M, Tokunaga K, Fujimoto T, Suzuki M, Nagashima M, Nakagawa H, Narita M, Kato Y, Igari H, Fujita K, Kato T, Hiyama K, Shindou K, Adachi T, Fukushima K, Nakamura-Uchiyama F, Hase R, Yoshimura Y, Yamato M, Nozaki Y, Ohmagari N, Suzuki M, Saito T, Iwami S, Suzuki T. Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection. Proc Natl Acad Sci U S A 2023; 120:e2314808120. [PMID: 38134196 PMCID: PMC10756199 DOI: 10.1073/pnas.2314808120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2023] [Accepted: 11/20/2023] [Indexed: 12/24/2023] Open
Abstract
Infectious virus shedding from individuals infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is used to estimate human-to-human transmission risk. Control of SARS-CoV-2 transmission requires identifying the immune correlates that protect infectious virus shedding. Mucosal immunity prevents infection by SARS-CoV-2, which replicates in the respiratory epithelium and spreads rapidly to other hosts. However, whether mucosal immunity prevents the shedding of the infectious virus in SARS-CoV-2-infected individuals is unknown. We examined the relationship between viral RNA shedding dynamics, duration of infectious virus shedding, and mucosal antibody responses during SARS-CoV-2 infection. Anti-spike secretory IgA antibodies (S-IgA) reduced viral RNA load and infectivity more than anti-spike IgG/IgA antibodies in infected nasopharyngeal samples. Compared with the IgG/IgA response, the anti-spike S-IgA post-infection responses affected the viral RNA shedding dynamics and predicted the duration of infectious virus shedding regardless of the immune history. These findings highlight the importance of anti-spike S-IgA responses in individuals infected with SARS-CoV-2 for preventing infectious virus shedding and SARS-CoV-2 transmission. Developing medical countermeasures to shorten S-IgA response time may help control human-to-human transmission of SARS-CoV-2 infection and prevent future respiratory virus pandemics.
Collapse
Affiliation(s)
- Sho Miyamoto
- Department of Pathology, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Takara Nishiyama
- Interdisciplinary Biology Laboratory, Division of Natural Science, Graduate School of Science, Nagoya University, Aichi464-8602, Japan
| | - Akira Ueno
- Department of Pathology, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Hyeongki Park
- Interdisciplinary Biology Laboratory, Division of Natural Science, Graduate School of Science, Nagoya University, Aichi464-8602, Japan
| | - Takayuki Kanno
- Department of Pathology, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Naotoshi Nakamura
- Interdisciplinary Biology Laboratory, Division of Natural Science, Graduate School of Science, Nagoya University, Aichi464-8602, Japan
| | - Seiya Ozono
- Department of Pathology, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Kazuyuki Aihara
- International Research Center for Neurointelligence, The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Tokyo113-0033, Japan
| | - Kenichiro Takahashi
- Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Yuuki Tsuchihashi
- Center for surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo162-8640, Japan
- Center for Field Epidemic Intelligence, Research and Professional Development, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Masahiro Ishikane
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo162-8655, Japan
| | - Takeshi Arashiro
- Department of Pathology, National Institute of Infectious Diseases, Tokyo162-8640, Japan
- Center for surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Shinji Saito
- Department of Pathology, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Akira Ainai
- Department of Pathology, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Yuichiro Hirata
- Department of Pathology, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Shun Iida
- Department of Pathology, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Harutaka Katano
- Department of Pathology, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Minoru Tobiume
- Department of Pathology, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Kenzo Tokunaga
- Department of Pathology, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Tsuguto Fujimoto
- Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Michiyo Suzuki
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo162-8655, Japan
| | - Maki Nagashima
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo162-8655, Japan
| | - Hidenori Nakagawa
- Department of Infectious Diseases, Osaka City General Hospital, Osaka534-0021, Japan
| | - Masashi Narita
- Division of Infectious Diseases, Department of Internal Medicine, Okinawa Prefectural Nanbu Medical Center and Children’s Medical Center, Okinawa901-1193, Japan
| | - Yasuyuki Kato
- Department of Infectious Diseases, International University of Health and Welfare Narita Hospital, Chiba286-0124, Japan
| | - Hidetoshi Igari
- Department of Infection Control, Chiba University Hospital, Chiba, Japan
| | - Kaori Fujita
- Department of Respiratory Medicine, National Hospital Organization Okinawa National Hospital, Okinawa901-2214, Japan
| | - Tatsuo Kato
- Department of Chest Disease, National Hospital Organization Nagara Medical Center, Gifu502-8558, Japan
| | - Kazutoshi Hiyama
- Department of Infectious Disease, National Hospital Organization Fukuoka-Higashi Medical Center, Fukuoka811-3195, Japan
| | - Keisuke Shindou
- Department of Pediatrics, Hirakata City Hospital, Osaka573-1013, Japan
| | - Takuya Adachi
- Department of Infectious Diseases, Tokyo Metropolitan Toshima Hospital, Tokyo173-0015, Japan
| | - Kazuaki Fukushima
- Department of Infectious Disease, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo113-8677, Japan
| | | | - Ryota Hase
- Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Chiba286-8523, Japan
| | - Yukihiro Yoshimura
- Division of Infectious Disease, Yokohama Municipal Citizen’s Hospital, Kanagawa221-0855, Japan
| | - Masaya Yamato
- Department of General Internal Medicine and Infectious Diseases, Rinku General Medical Center 598-8577, Osaka, Japan
| | - Yasuhiro Nozaki
- Department of Respiratory Medicine, Tokoname City Hospital, Aichi479-8510, Japan
| | - Norio Ohmagari
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo162-8655, Japan
| | - Motoi Suzuki
- Center for surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Tomoya Saito
- Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| | - Shingo Iwami
- Interdisciplinary Biology Laboratory, Division of Natural Science, Graduate School of Science, Nagoya University, Aichi464-8602, Japan
- Institute of Mathematics for Industry, Kyushu University, Fukuoka819-0395, Japan
- Institute for the Advanced Study of Human Biology, Kyoto University, Kyoto606-8501, Japan
- Interdisciplinary Theoretical and Mathematical Sciences Program, RIKEN, Saitama351-0198, Japan
- NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo135-8550, Japan
- Science Groove Inc., Fukuoka810-0041, Japan
| | - Tadaki Suzuki
- Department of Pathology, National Institute of Infectious Diseases, Tokyo162-8640, Japan
| |
Collapse
|
5
|
Murakami Y, Ogashiwa H, Nozaki Y, Ueda T, Nakajima K, Morosawa M, Doi M, Makino M, Takesue Y. Judicious ending of isolation based on reverse transcription-polymerase chain reaction (RT-PCR) cycle threshold only for patients with coronavirus disease 2019 (COVID-19) requiring in-hospital therapy for longer than 20 days after symptom onset. J Infect Chemother 2023:S1341-321X(23)00117-4. [PMID: 37209841 DOI: 10.1016/j.jiac.2023.05.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2023] [Revised: 04/19/2023] [Accepted: 05/01/2023] [Indexed: 05/22/2023]
Abstract
BACKGROUND For patients with coronavirus disease 2019 (COVID-19) requiring hospitalization, extending isolation is warranted. As a cautious protocol, ending isolation based on polymerase chain reaction cycle threshold (Ct) value was introduced for patients requiring therapy for >20 days after symptom onset. METHOD We compared a Ct-based strategy using Smart Gene® between March 2022 and January 2023 with a preceding control period (March 2021 to February 2022) when two consecutive negative reverse transcription-polymerase chain reaction tests using FilmArray® were required for ending isolation. Ct was evaluated on day 21, and ending isolation was permitted in patients with Ct ≥ 38. Although patients with Ct 35-37 were transferred to a non-COVID-19 ward, isolation was continued. RESULTS The duration of stay on a COVID-19 ward in the Ct group was 9.7 days shorter than that in controls. The cumulative number of tests was 3.7 in controls and 1.2 in the Ct group. There was no nosocomial transmission after ending isolation in either group. The number of days from symptom onset to testing was 20.7 ± 2.1 in Ct group, and five patients had Ct < 35, nine Ct 35-37, and 71 Ct ≥ 38. No patients were moderately or severely immunocompromised. Steroid use was an independent risk factor for prolonged low Ct (odds ratio 9.40, 95% confidence interval 2.31-38.15, p = 0.002) CONCLUSIONS: The efficacy of ending isolation based on Ct values could improve bed utilization without the risk of transmission among patients with COVID-19 requiring therapy for >20 days after symptom onset.
Collapse
Affiliation(s)
- Yasushi Murakami
- Department of Respiratory Medicine, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Hitoshi Ogashiwa
- Department of Clinical Technology, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Yasuhiro Nozaki
- Department of Respiratory Medicine, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Takashi Ueda
- Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, 663-8501, Japan.
| | - Kazuhiko Nakajima
- Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, 663-8501, Japan.
| | - Mika Morosawa
- Department of Respiratory Medicine, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8560, Japan.
| | - Miki Doi
- Department of Clinical Technology, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, Aichi, 479-8510, Japan.
| | - Miyuki Makino
- Department of Infection Control and Prevention, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, 479-8510, Japan.
| | - Yoshio Takesue
- Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, 663-8501, Japan; Department of Clinical Infectious Diseases, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname, 479-8510, Japan.
| |
Collapse
|
6
|
Morosawa M, Ueda T, Nakajima K, Inoue T, Toyama M, Ogasiwa H, Doi M, Nozaki Y, Murakami Y, Ishii M, Takesue Y. Comparison of antibiotic use and antibiotic resistance between a community hospital and tertiary care hospital for evaluation of the antimicrobial stewardship program in Japan. PLoS One 2023; 18:e0284806. [PMID: 37093821 PMCID: PMC10124824 DOI: 10.1371/journal.pone.0284806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Accepted: 04/06/2023] [Indexed: 04/25/2023] Open
Abstract
Assessment of risk-adjusted antibiotic use (AU) is recommended to evaluate antimicrobial stewardship programs (ASPs). We aimed to compare the amount and diversity of AU and antimicrobial susceptibility of nosocomial isolates between a 266-bed community hospital (CH) and a 963-bed tertiary care hospital (TCH) in Japan. The days of therapy/100 bed days (DOT) was measured for four classes of broad-spectrum antibiotics predominantly used for hospital-onset infections. The diversity of AU was evaluated using the modified antibiotic heterogeneity index (AHI). With 10% relative DOT for fluoroquinolones and 30% for each of the remaining three classes, the modified AHI equals 1. Multidrug resistance (MDR) was defined as resistance to ≥ 3 anti-Pseudomonas antibiotic classes. The DOT was significantly higher in the TCH than in the CH (10.85 ± 1.32 vs. 3.89 ± 0.93, p < 0.001). For risk-adjusted AU, the DOT was 6.90 ± 1.50 for acute-phase medical wards in the CH, and 8.35 ± 1.05 in the TCH excluding the hematology department. In contrast, the DOT of antibiotics for community-acquired infections was higher in the CH than that in the TCH. As quality assessment of AU, higher modified AHI was observed in the TCH than in the CH (0.832 ± 0.044 vs. 0.721 ± 0.106, p = 0.003), indicating more diverse use in the TCH. The MDR rate in gram-negative rods was 5.1% in the TCH and 3.4% in the CH (p = 0.453). No significant difference was demonstrated in the MDR rate for Pseudomonas aeruginosa and Enterobacteriaceae species between hospitals. Broad-spectrum antibiotics were used differently in the TCH and CH. However, an increased antibiotic burden in the TCH did not cause poor susceptibility, possibly because of diversified AU. Considering the different patient populations, benchmarking AU according to the facility type is promising for inter-hospital comparisons of ASPs.
Collapse
Affiliation(s)
- Mika Morosawa
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
- Department of Respiratory Medicine, Tokoname City Hospital, Tokoname, Aichi, Japan
| | - Takashi Ueda
- Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Japan
| | - Kazuhiko Nakajima
- Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Japan
| | - Tomoko Inoue
- Department of Pharmacy, Tokoname City Hospital, Tokoname, Aichi, Japan
| | - Masanobu Toyama
- Department of Pharmacy, Tokoname City Hospital, Tokoname, Aichi, Japan
| | - Hitoshi Ogasiwa
- Department of Clinical Technology, Tokoname City Hospital, Tokoname, Aichi, Japan
| | - Miki Doi
- Department of Clinical Technology, Tokoname City Hospital, Tokoname, Aichi, Japan
| | - Yasuhiro Nozaki
- Department of Respiratory Medicine, Tokoname City Hospital, Tokoname, Aichi, Japan
| | - Yasushi Murakami
- Department of Respiratory Medicine, Tokoname City Hospital, Tokoname, Aichi, Japan
| | - Makoto Ishii
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yoshio Takesue
- Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Japan
- Department of Clinical Infectious Diseases, Tokoname City Hospital, Tokoname, Japan
| |
Collapse
|
7
|
Nozaki Y, Fujimoto S, Takahashi D, Kawaguchi YO, Kudo A, Aoshima C, Kamo Y, Takamura K, Hiki M, Dohi T, Tomizawa N, Minamino T. Additional clinical impact of plaque analysis for on-site CT-derived FFR in coronary CT angiography on midterm prognosis. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
We previously reported that per-patient on-site computed tomography-fractional flow reserve (CT-FFR), which can be acquired on-site workstation using fluid structure interaction during the multiple optimal diastolic phases measured 1 to 2 cm distal to a target lesion may be feasible for risk stratification based on future cardiac events for patients who did not undergo planned revascularization. However, per-vessel CT-FFR and the additional impact of plaque analysis on CT-FFR have not been evaluated.
Purpose
The aim of this study is to assess the clinical and additional impact of novel plaque analysis using labeling method for per-vessel CT-FFR on midterm prognosis.
Methods
A total of 254 consecutive patients with 354 vessels showing 50–90% stenosis but not revascularized within 90 days from coronary CT angiography (CCTA) on 320-row CT were retrospectively analyzed and followed during a median follow up 3.6 years. Plaque characteristics by labeling method (necrotic core/total plaque volume (% necrotic core), non-calcified plaque (NCP)/vessel volume (%NCP), and total plaque/vessel volume (%total plaque) for both total vessel volume (mm3) and at minimum lumen area (MLA, mm2)), positive remodeling (PR) and CT-FFR were analyzed on per-target vessels. The endpoint was vessel oriented-composite outcome (VOCO), including cardiac death, non-fatal MI, and unplanned revascularization.
Results
The incidence of VOCO occurred in 6.8% (24/354). In the cox proportional hazard model, a multivariate analysis identified CT-FFR≤0.80 was the most associated factor with VOCO (all values <0.01 for other plaque morphologies), but %necrotic core, %NCP, %total plaque at MLA and PR were significantly independent of CT-FFR≤0.80. (%necrotic core HR; 3.43 (p<0.01 [95% confidence interval (CI) 1.42–8.29]), %NCP HR; 4.05 (p=0.03 [95% CI 1.19–13.71]), %total plaque at MLA HR; 2.82 (p=0.02 [95% CI 1.18–6.76]), and PR HR; 2.90 (p<0.01 [95% CI 1.30–6.51]), respectively.)
Conclusion
From a view point of clinical outcomes for vessels with moderate to severe stenosis but not revascularized at initial CCTA, CT-FFR demonstrated the significant impact on per-vessel analysis. Moreover, %necrotic core, %NCP and %total plaque at MLA analyzed by labeling method provided better prognostic value in addition to CT-FFR.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- Y Nozaki
- Juntendo University, Graduate School of Medicine, Hongo, Bunkyo-ku , Tokyo , Japan
| | - S Fujimoto
- Juntendo University, Graduate School of Medicine, Hongo, Bunkyo-ku , Tokyo , Japan
| | - D Takahashi
- Juntendo University, Graduate School of Medicine, Hongo, Bunkyo-ku , Tokyo , Japan
| | - Y O Kawaguchi
- Juntendo University, Graduate School of Medicine, Hongo, Bunkyo-ku , Tokyo , Japan
| | - A Kudo
- Juntendo University, Graduate School of Medicine, Hongo, Bunkyo-ku , Tokyo , Japan
| | - C Aoshima
- Juntendo University, Graduate School of Medicine, Hongo, Bunkyo-ku , Tokyo , Japan
| | - Y Kamo
- Juntendo University, Graduate School of Medicine, Hongo, Bunkyo-ku , Tokyo , Japan
| | - K Takamura
- Juntendo University, Graduate School of Medicine, Hongo, Bunkyo-ku , Tokyo , Japan
| | - M Hiki
- Juntendo University, Graduate School of Medicine, Hongo, Bunkyo-ku , Tokyo , Japan
| | - T Dohi
- Juntendo University, Graduate School of Medicine, Hongo, Bunkyo-ku , Tokyo , Japan
| | - N Tomizawa
- Juntendo University Graduate School of Medicine, Department of Radiology , Tokyo , Japan
| | - T Minamino
- Juntendo University Graduate School of Medicine, Department of Radiology , Tokyo , Japan
| |
Collapse
|
8
|
Taniguchi C, Saka H, Oki M, Tachibana K, Nozaki Y, Suzuki Y, Tanaka H, Oze I. Relationship between tobacco craving and quitting smoking using Tobacco Craving Index (TCI) in Japanese smoking cessation therapy. Tob Induc Dis 2021. [DOI: 10.18332/tid/141360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
9
|
Shiono Y, Matsuo H, Fujita H, Tanaka N, Ogasawara Y, Kawamura I, Katayama Y, Matsuo A, Kawase Y, Kakuta T, Takashima H, Yokoi H, Ohira H, Suwa S, Oguri M, Yamamoto F, Kubo T, Akasaka T, Shiono Y, Katayama Y, Hironori K, Kubo T, Akasaka T, Tanaka N, Yamashita J, Fujita H, Matsuo A, Matsuo H, Kawase Y, Kawamura I, Kakuta T, Hoshino M, Sugano T, Takashima H, Amano T, Yokoi H, Yamamoto Y, Nozaki Y, Machida M, Kobori M, Kikuchi T, Ohira H, Yoshino H, Ishiguro H, Wakabayashi Y, Kondo T, Terai H, Suwa T, Kimura T, Kawajiri T, Hirohata A, Uemura S, Neishi Y, Sakamoto T, Yamada M, Okeie K, Hishikari K, Oguri M, Uetani T, Saegusa T, Yamamoto F, Yamada M. Diagnostic Accuracy of Diastolic Fractional Flow Reserve for Functional Evaluation of Coronary Stenosis. JACC: Asia 2021; 1:230-241. [PMID: 36338166 PMCID: PMC9627917 DOI: 10.1016/j.jacasi.2021.07.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 06/28/2021] [Accepted: 07/08/2021] [Indexed: 01/10/2023]
Abstract
Background In the resting conditions, narrowing the window of coronary pressure measurements from the whole cardiac cycle to diastole improves diagnostic performance of coronary pressure–derived physiological index. However, whether this also applies to the hyperemic conditions has not yet been thoroughly evaluated. Objectives The purpose of this study was to assess whether diastolic fractional flow reserve (diastolic FFR) has better diagnostic performance in identifying ischemia-causing coronary lesions than conventional FFR in a prospective, multicenter, and independent core laboratory–based environment. Methods In this prospective multicenter registry at 29 Japanese centers, we compared the diagnostic performance of FFR, diastolic FFR, resting distal to aortic coronary pressure (Pd/Pa), and diastolic pressure ratio (dPR) using myocardial perfusion scintigraphy (MPS) as the reference standard in 378 patients with single-vessel coronary disease. Results Inducible myocardial ischemia was found on MPS in the relevant myocardial territory of the target vessel in 85 patients (22%). In the receiver-operating curve analyses, diastolic FFR had comparable area under the curve (AUC) compared with FFR (AUCdiastolic FFR: 0.66; 95% confidence interval [CI]: 0.58-0.73, vs AUCFFR: 0.66; 95% CI: 0.58-0.74, P = 0.624). FFR and diastolic FFR showed significantly larger AUCs than resting Pd/Pa (0.62; 95% CI: 0.54-0.70; P = 0.033 and P = 0.046) but did not show significantly larger AUCs than dPR (0.62; 95% CI: 0.55-0.70; P = 0.102 and P = 0.113). Conclusions Diastolic FFR showed a similar diagnostic performance to FFR as compared with MPS. This result reaffirms the use of FFR as the most accurate invasive physiological lesion assessment. (Diagnostic accuracy of diastolic fractional flow reserve (d-FFR) for functional evaluation of coronary stenosis; UMIN000015906)
Collapse
|
10
|
Taniguchi C, Saka H, Oze I, Nakamura S, Nozaki Y, Tanaka H. Relationship between the strength of craving as assessed by the Tobacco Craving Index and success of quitting smoking in Japanese smoking cessation therapy. PLoS One 2020; 15:e0243374. [PMID: 33284809 PMCID: PMC7721195 DOI: 10.1371/journal.pone.0243374] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Accepted: 11/19/2020] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND We previously developed the Tobacco Craving Index (TCI) to assess craving of smokers. In the present study, we validated the relationship between the TCI grade over the 5 sessions of Japanese smoking cessation therapy (SCT) and success of quitting smoking among 889 Japanese patients. METHODS The Japanese SCT consists of 5 sessions of SCT (first session and sessions 2, 4, 8 and 12 weeks later). In the TCI questionnaire, patients are asked to rate their strength of craving and frequency of craving, each on a four-point Likert scale. Patients are classified into one of four grades based on their responses (0, I, II, III, with III indicating severe craving). The TCI questionnaire was administered to each participant at each session of the SCT. This study included participants of Japanese SCT who answered the TCI at the first session of the SCT at five Japanese smoking cessation clinics. Patients who dropped out of the SCT from the second to the fifth sessions were considered to have failed smoking cessation. To elucidate how much the TCI grade predicts smoking status at the last session, we performed multivariate logistic regression analysis with adjustment for confounding factors. RESULTS Participants who had higher TCI grade(III) in the 2nd through 5th sessions showed significantly lower probability for success of quitting smoking than those who had lower TCI grades(0 or I) (adjusted odds ratio: 2nd session: 0.30, 3rd session: 0.15, 4th session: 0.06, 5th session: 0.02). CONCLUSIONS We validated the usefulness of the TCI grade for assessing probability of quitting smoking by using a large number of smoking cessation settings.
Collapse
Affiliation(s)
- Chie Taniguchi
- College of Nursing, Aichi Medical University, Nagakute-city, Aichi, Japan
- Department of Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya-city, Aichi, Japan
| | - Hideo Saka
- Department of Respiratory Medicine, Matsunami General Hospital, Hashima-gun, Gifu, Japan
- Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya-city, Aichi, Japan
| | - Isao Oze
- Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer Center Research Institute, Nagoya-city, Aichi, Japan
| | - Sumie Nakamura
- Department of Nursing, National Hospital Organization Nagoya Medical Center, Nagoya-city, Aichi, Japan
| | - Yasuhiro Nozaki
- Department of Respiratory Medicine, Japan Community Healthcare Organization Chukyo Hospital, Nagoya-city, Aichi, Japan
- Department of Respiratory Medicine, Tokoname Municipal Hospital, Tokoname-city, Aichi, Japan
| | - Hideo Tanaka
- Fujiidera Public Health Center of Osaka Prefecture, Fujidera-city, Osaka, Japan
| |
Collapse
|
11
|
Goto Y, Takahashi K, Saito H, Ogasawara T, Shindoh J, Kimura T, Sugino Y, Kojima E, Nomura F, Nakanishi T, Nozaki Y, Takeyama Y, Imaizumi K, Hasegawa Y. P1.01-25 Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
12
|
Tatemoto K, Nozaki Y, Tsuda R, Kaneko S, Tomura K, Furuno M, Ogasawara H, Edamura K, Takagi H, Iwamura H, Noguchi M, Naito T. Endogenous protein and enzyme fragments induce immunoglobulin E-independent activation of mast cells via a G protein-coupled receptor, MRGPRX2. Scand J Immunol 2018; 87:e12655. [PMID: 29484687 DOI: 10.1111/sji.12655] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2017] [Accepted: 02/20/2018] [Indexed: 12/31/2022]
Abstract
Mast cells play a central role in inflammatory and allergic reactions by releasing inflammatory mediators through 2 main pathways, immunoglobulin E-dependent and E-independent activation. In the latter pathway, mast cells are activated by a diverse range of basic molecules (collectively known as basic secretagogues) through Mas-related G protein-coupled receptors (MRGPRs). In addition to the known basic secretagogues, here, we discovered several endogenous protein and enzyme fragments (such as chaperonin-10 fragment) that act as bioactive peptides and induce immunoglobulin E-independent mast cell activation via MRGPRX2 (previously known as MrgX2), leading to the degranulation of mast cells. We discuss the possibility that MRGPRX2 responds various as-yet-unidentified endogenous ligands that have specific characteristics, and propose that MRGPRX2 plays an important role in regulating inflammatory responses to endogenous harmful stimuli, such as protein breakdown products released from damaged or dying cells.
Collapse
Affiliation(s)
- K Tatemoto
- Department of Molecular Physiology, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan
| | - Y Nozaki
- Pharmaceutical Frontier Research Laboratories, Japan Tobacco Inc., Yokohama, Japan
| | - R Tsuda
- Department of Molecular Physiology, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan
| | - S Kaneko
- Department of Molecular Physiology, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan
| | - K Tomura
- Pharmaceutical Frontier Research Laboratories, Japan Tobacco Inc., Yokohama, Japan
| | - M Furuno
- Pharmaceutical Frontier Research Laboratories, Japan Tobacco Inc., Yokohama, Japan
| | - H Ogasawara
- Pharmaceutical Frontier Research Laboratories, Japan Tobacco Inc., Yokohama, Japan
| | - K Edamura
- Pharmaceutical Frontier Research Laboratories, Japan Tobacco Inc., Yokohama, Japan
| | - H Takagi
- Pharmaceutical Frontier Research Laboratories, Japan Tobacco Inc., Yokohama, Japan
| | - H Iwamura
- Pharmaceutical Frontier Research Laboratories, Japan Tobacco Inc., Yokohama, Japan
| | - M Noguchi
- Pharmaceutical Frontier Research Laboratories, Japan Tobacco Inc., Yokohama, Japan
| | - T Naito
- Pharmaceutical Frontier Research Laboratories, Japan Tobacco Inc., Yokohama, Japan
| |
Collapse
|
13
|
Taniguchi C, Tanaka H, Saka H, Oze I, Tachibana K, Nozaki Y, Suzuki Y, Sakakibara H. Changes in self-efficacy associated with success in quitting smoking in participants in Japanese smoking cessation therapy. Int J Nurs Pract 2018; 24:e12647. [DOI: 10.1111/ijn.12647] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2017] [Revised: 01/22/2018] [Accepted: 02/16/2018] [Indexed: 01/02/2023]
Affiliation(s)
- Chie Taniguchi
- Department of Nursing, Japan and Visiting Scholar, Nagoya Medical Center, Clinical Research Center; Sugiyama Jogakuen University; Nagoya Japan
| | - Hideo Tanaka
- Kishiwada Public Health Center of Osaka Prefecture, Japan and Visiting Scholar, Division of Epidemiology and Prevention; Aichi Cancer Center Research Institute; Nagoya Japan
| | - Hideo Saka
- Department of Respiratory Medicine and Medical Oncology; National Hospital Organization Nagoya Medical Center; Nagoya Japan
| | - Isao Oze
- Division of Molecular & Clinical Epidemiology; Aichi Cancer Center Research Institute; Nagoya Japan
| | - Kazunobu Tachibana
- Department of Education and Training, Department of Respiratory Medicine; National Hospital Organization Kinki-Chuo Chest Medical Center; Sakai Japan
| | - Yasuhiro Nozaki
- Department of Respiratory Medicine; Japan Community Healthcare Organization Chukyo Hospital; Osaka Japan
| | - Yukio Suzuki
- Department of Respiratory Medicine; Kitasato University Kitasato Institute Hospital; Tokyo Japan
| | - Hisataka Sakakibara
- Department of Nursing; Nagoya University Graduate School of Medicine; Nagoya Japan
| |
Collapse
|
14
|
Maekawa M, Watanabe A, Iwayama Y, Kimura T, Hamazaki K, Balan S, Ohba H, Hisano Y, Nozaki Y, Ohnishi T, Toyoshima M, Shimamoto C, Iwamoto K, Bundo M, Osumi N, Takahashi E, Takashima A, Yoshikawa T. Polyunsaturated fatty acid deficiency during neurodevelopment in mice models the prodromal state of schizophrenia through epigenetic changes in nuclear receptor genes. Transl Psychiatry 2017; 7:e1229. [PMID: 28872641 PMCID: PMC5639238 DOI: 10.1038/tp.2017.182] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2017] [Revised: 06/26/2017] [Accepted: 07/06/2017] [Indexed: 12/13/2022] Open
Abstract
The risk of schizophrenia is increased in offspring whose mothers experience malnutrition during pregnancy. Polyunsaturated fatty acids (PUFAs) are dietary components that are crucial for the structural and functional integrity of neural cells, and PUFA deficiency has been shown to be a risk factor for schizophrenia. Here, we show that gestational and early postnatal dietary deprivation of two PUFAs-arachidonic acid (AA) and docosahexaenoic acid (DHA)-elicited schizophrenia-like phenotypes in mouse offspring at adulthood. In the PUFA-deprived mouse group, we observed lower motivation and higher sensitivity to a hallucinogenic drug resembling the prodromal symptoms in schizophrenia. Furthermore, a working-memory task-evoked hyper-neuronal activity in the medial prefrontal cortex was also observed, along with the downregulation of genes in the prefrontal cortex involved in oligodendrocyte integrity and the gamma-aminobutyric acid (GABA)-ergic system. Regulation of these genes was mediated by the nuclear receptor genes Rxr and Ppar, whose promoters were hyper-methylated by the deprivation of dietary AA and DHA. In addition, the RXR agonist bexarotene upregulated oligodendrocyte- and GABA-related gene expression and suppressed the sensitivity of mice to the hallucinogenic drug. Notably, the expression of these nuclear receptor genes were also downregulated in hair-follicle cells from schizophrenia patients. These results suggest that PUFA deficiency during the early neurodevelopmental period in mice could model the prodromal state of schizophrenia through changes in the epigenetic regulation of nuclear receptor genes.
Collapse
Affiliation(s)
- M Maekawa
- Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan,Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan. E-mail: or
| | - A Watanabe
- Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan
| | - Y Iwayama
- Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan
| | - T Kimura
- Department of Alzheimer's Disease Research, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Aichi, Japan
| | - K Hamazaki
- Department of Public Health, Faculty of Medicine, University of Toyama, Toyama, Japan
| | - S Balan
- Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan
| | - H Ohba
- Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan
| | - Y Hisano
- Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan
| | - Y Nozaki
- Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan
| | - T Ohnishi
- Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan
| | - M Toyoshima
- Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan
| | - C Shimamoto
- Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan
| | - K Iwamoto
- Department of Molecular Brain Science, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
| | - M Bundo
- Department of Molecular Brain Science, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
| | - N Osumi
- Department of Developmental Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - E Takahashi
- Support Unit for Animal Resources Development, RIKEN Brain Science Institute, Saitama, Japan
| | - A Takashima
- Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan,Department of Life Sciences, Graduate School of Science, Gakushuin University, Tokyo, Japan
| | - T Yoshikawa
- Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan,Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan. E-mail: or
| |
Collapse
|
15
|
Kobayashi D, Yoshikawa T, Matsuo M, Iguchi R, Maekawa S, Saitoh E, Nozaki Y. Spin Current Generation Using a Surface Acoustic Wave Generated via Spin-Rotation Coupling. Phys Rev Lett 2017; 119:077202. [PMID: 28949686 DOI: 10.1103/physrevlett.119.077202] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/20/2017] [Indexed: 06/07/2023]
Abstract
We demonstrate the generation of alternating spin current (SC) via spin-rotation coupling (SRC) using a surface acoustic wave (SAW) in a Cu film. Ferromagnetic resonance caused by injecting SAWs was observed in a Ni-Fe film attached to a Cu film, with the resonance further found to be suppressed through the insertion of a SiO_{2} film into the interface. The intensity of the resonance depended on the angle between the wave vector of the SAW and the magnetization of the Ni-Fe film. This angular dependence is explicable in terms of the presence of spin transfer torque from a SC generated via SRC.
Collapse
Affiliation(s)
- D Kobayashi
- Department of Physics, Keio University, Yokohama 223-8522, Japan
| | - T Yoshikawa
- Department of Physics, Keio University, Yokohama 223-8522, Japan
| | - M Matsuo
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai 319-1195, Japan
- Advanced Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan
| | - R Iguchi
- National Institute for Materials Science, Tsukuba 305-0047, Japan
- Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan
| | - S Maekawa
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai 319-1195, Japan
| | - E Saitoh
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai 319-1195, Japan
- Advanced Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan
- Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan
- Center for Spintronics Research Network, Tohoku University, Sendai 980-8577, Japan
| | - Y Nozaki
- Department of Physics, Keio University, Yokohama 223-8522, Japan
- Center for Spintronics Research Network, Keio University, Yokohama 223-8522, Japan
| |
Collapse
|
16
|
Taniguchi C, Tanaka H, Saka H, Oze I, Tachibana K, Nozaki Y, Suzuki Y, Sakakibara H. Cognitive, behavioural and psychosocial factors associated with successful and maintained quit smoking status among patients who received smoking cessation intervention with nurses’ counselling. J Adv Nurs 2017; 73:1681-1695. [DOI: 10.1111/jan.13258] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/02/2017] [Indexed: 11/26/2022]
Affiliation(s)
- Chie Taniguchi
- Department of Nursing; Sugiyama Jogakuen University; Nagoya Japan
- Department of Nursing; Nagoya University Graduate School of Medicine; Nagoya Japan
- Nagoya Medical Center; Clinical Research Center; Nagoya Japan
| | - Hideo Tanaka
- Division of Epidemiology and Prevention; Aichi Cancer Center Research Institute; Nagoya Japan
- Department of Epidemiology; Nagoya University Graduate School of Medicine; Japan
| | - Hideo Saka
- Department of Respiratory Medicine and Medical Oncology; National Hospital Organization Nagoya Medical Center; Nagoya Japan
| | - Isao Oze
- Division of Epidemiology and Prevention; Aichi Cancer Center Research Institute; Nagoya Japan
| | - Kazunobu Tachibana
- Department of Education and Training; Department of Respiratory Medicine; National Hospital Organization Kinki-Chuo Chest Medical Center; Sakai Japan
| | - Yasuhiro Nozaki
- Department of Respiratory Medicine; Japan Community Healthcare Organization Chukyo Hospital; Nagoya Japan
| | - Yukio Suzuki
- Department of Respiratory Medicine; Kitasato University Kitasato Institute Hospital; Tokyo Japan
| | - Hisataka Sakakibara
- Department of Nursing; Nagoya University Graduate School of Medicine; Nagoya Japan
| |
Collapse
|
17
|
Kajikawa S, Noda K, Nozaki Y. Necrotizing tracheobronchitis associated with rheumatoid arthritis. Respir Med Case Rep 2016; 20:31-33. [PMID: 27896063 PMCID: PMC5121158 DOI: 10.1016/j.rmcr.2016.11.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Revised: 11/08/2016] [Accepted: 11/08/2016] [Indexed: 02/01/2023] Open
Abstract
We report a case of necrotizing tracheobronchitis with rheumatoid arthritis. A 64 year-old-man presented with dry cough and was initially diagnosed with community-acquired pneumonia. The patient was admitted; he received initial antibiotic treatment. The treatment was effective and the symptoms worsened. Bronchoscopy was performed for more thorough examination. It showed that white and soft tissues were on the trachea-bronchus. Transbronchial biopsy of the tracheal lesions revealed necrotic tissue with squamous metaplasia and inflammatory cells. Whereas, symmetrical arthralgia of multiple joints of the limbs was noted and rheumatoid factor and anti-cyclic citrullinated peptide antibody of levels were high. According to these results, the patient was diagnosed with rheumatoid arthritis. In this case, necrotizing tracheobronchitis occurred as a result of systemic inflammation associated with rheumatoid arthritis. An acute exacerbation of the patient's respiratory condition was treated with steroid therapy. Tracheal findings and respiratory symptoms were improved by steroid therapy.
Collapse
Affiliation(s)
| | - Kazushi Noda
- Department of Respiratory Medicine, Chukyo Hospital, Japan
| | | |
Collapse
|
18
|
Nozaki Y, Koyasu M. The location of emotional competence in the multiple intelligences theory seen from laypersons. Personality and Individual Differences 2016. [DOI: 10.1016/j.paid.2016.05.242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
19
|
|
20
|
Kato T, Morise M, Ando M, Kojima E, Ogasawara T, Suzuki R, Shindoh J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Hase T, Kondo M, Saito H, Hasegawa Y. Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy? J Cancer Res Clin Oncol 2016; 142:1629-40. [PMID: 27166967 DOI: 10.1007/s00432-016-2170-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Accepted: 04/18/2016] [Indexed: 01/06/2023]
Abstract
PURPOSE Predicting the feasibility of platinum-based chemotherapy remains an important issue in elderly (over 70 years) patients with non-small cell lung cancer (NSCLC). The aim of this study was to identify the risk factors for the early serious adverse events (SAEs) (during cycles 1-2) in elderly receiving platinum-based chemotherapy, and to explore the clinical characteristics of patients who require early treatment termination without progressive disease (PD). METHODS One hundred and ninety-eight consecutive elderly NSCLC patients receiving platinum-based chemotherapy were retrospectively reviewed. RESULTS The median age was 73 years (range 70-83). 161 (81 %) were males, and 190 (95 %) were PS 0-1. Fifty-one (29 %) and 39 (19 %) patients developed early non-hematological SAEs and hematological SAEs, respectively. Multivariate analysis identified low serum albumin (<3.0 g/dl) as an independent risk factor for non-hematological SAEs, while low creatinine clearance (<45 ml/min) for hematological SAEs. In all, 24 (12 %) patients needed early treatment termination without PD. The major reason for this event was the development of non-hematological SAEs (4.5 %), followed by grade 2 non-hematological adverse events (AEs) (3 %). In multivariate analysis, age over 75 years and low serum albumin were associated with this event. The median overall survival (OS) in patients with this event was only 6.0 months, while the development of early SAE was not associated with poor OS. CONCLUSION Baseline serum albumin might be useful for predicting the feasibility of platinum-based chemotherapy, and the risk estimation of early treatment termination without PD might be beneficial for the treatment selection in elderly NSCLC patients.
Collapse
Affiliation(s)
- Toshio Kato
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Masahiro Morise
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
| | - Masahiko Ando
- Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan
| | - Eiji Kojima
- Department of Respiratory Medicine, Komaki Municipal Hospital, Komaki, Japan
| | - Tomohiko Ogasawara
- Department of Respiratory Medicine, Nagoya Daini Red Cross Hospital, Nagoya, Japan
| | - Ryujiro Suzuki
- Department of Respiratory Medicine, Toyohashi Municipal Hospital, Toyohashi, Japan
| | - Joe Shindoh
- Department of Respiratory Medicine, Ogaki Municipal Hospital, Ogaki, Japan
| | - Masami Matsumoto
- Department of Respiratory Medicine, Ichinomiya Municipal Hospital, Ichinomiya, Japan
| | - Yasuteru Sugino
- Department of Respiratory Medicine, Toyota Memorial Hospital, Toyota, Japan
| | - Masahiro Ogawa
- Department of Respiratory Medicine, Handa City Hospital, Handa, Japan
| | - Yasuhiro Nozaki
- Department of Respiratory Medicine, Chukyo Hospital, Nagoya, Japan
| | - Tetsunari Hase
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Masashi Kondo
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| | - Hiroshi Saito
- Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Okazaki, Japan
| | - Yoshinori Hasegawa
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
| |
Collapse
|
21
|
Hidehiko S, Nishiguchi S, Fukutani N, Adachi D, Tashiro Y, Hotta T, Morino S, Nozaki Y, Hirata H, Yamaguchi M, Aoyama T. O-015: Health literacy is associated with frailty stage in community-dwelling elderly people. Eur Geriatr Med 2015. [DOI: 10.1016/s1878-7649(15)30029-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
22
|
Morino S, Nishiguchi S, Fukutani N, Adachi D, Tashiro Y, Hotta T, Shirooka H, Nozaki Y, Hirata H, Yamaguchi M, Matsumoto D, Aoyama T. Association between pelvic asymmetry and lumbopelvic pain during pregnancy. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.1906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Mishima S, Nozaki Y, Mikami S, Kihira E, Iikura M, Koketsu R, Sugiyama H, Masuda T, Kaname H, Egami Y, Nakayama T, Hasuo K, Nakamura H, Igari T, Watanabe K, Nagata N, Sakurai T, Yokoi C, Kobayakawa M, Kojima Y, Akiyama J, Imamura M, Masaki N, Yanase M. Diffuse Liver Metastasis of Small-Cell Lung Cancer Presenting as Acute Liver Failure and Diagnosed by Transjugular Liver Biopsy: A Rare Case in Whom Nodular Lesions Were Detected by Enhanced CT Examination. Case Rep Gastroenterol 2015; 9:81-7. [PMID: 25969674 PMCID: PMC4427142 DOI: 10.1159/000381140] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Small-cell lung cancer (SCLC) is a subgroup of lung cancer with a high frequency of liver metastasis, which is a predictor of poor prognosis. Diffuse liver metastases of SCLC with no visible nodular lesions in the liver when examined using computed tomography (CT) are relatively rare; however, a few cases with rapid progression to acute liver failure that were diagnosed after death have been reported. In this paper, we report a 63-year-old man with diffuse liver metastases of SCLC that were histologically diagnosed using a transjugular liver biopsy while the patient was alive, even though no lesions were visible during a contrast-enhanced CT examination.
Collapse
Affiliation(s)
- S Mishima
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
| | - Y Nozaki
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
| | - S Mikami
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
| | - E Kihira
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
| | - M Iikura
- Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
| | - R Koketsu
- Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
| | - H Sugiyama
- Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
| | - T Masuda
- Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan
| | - H Kaname
- Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan
| | - Y Egami
- Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan
| | - T Nakayama
- Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan
| | - K Hasuo
- Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan
| | - H Nakamura
- Department of Pathology, National Center for Global Health and Medicine, Tokyo, Japan
| | - T Igari
- Department of Pathology, National Center for Global Health and Medicine, Tokyo, Japan
| | - K Watanabe
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
| | - N Nagata
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
| | - T Sakurai
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
| | - C Yokoi
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
| | - M Kobayakawa
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
| | - Y Kojima
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
| | - J Akiyama
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
| | - M Imamura
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
| | - N Masaki
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
| | - M Yanase
- Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo, Japan
| |
Collapse
|
24
|
Kato T, Morise M, Ando M, Kojima E, Ogasawara T, Suzuki R, Shindoh J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Kondo M, Saito H, Hasegawa Y. Can we Predict Severe Adverse Events (Saes) and Clarify Unfit Populations for Platinum-Based Chemotherapy in Elderly Patients (Over 70 Years of Age) with Advanced Non-Small Cell Lung Cancer (Nsclc)? (Cjlsg 1203 Trial). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Adachi D, Fukutani N, Nishiguchi S, Hotta T, Morino S, Tashiro Y, Hirata H, Nozaki Y, Shirooka H, Yamaguchi M, Yamada M, Aoyama T. P218: Differences in chest wall mobility and respiratory function among age groups: a cross-sectional study of the healthy elderly. Eur Geriatr Med 2014. [DOI: 10.1016/s1878-7649(14)70392-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
26
|
Taniguchi C, Tanaka H, Nakamura N, Saka H, Oze I, Ito H, Tachibana K, Tokoro A, Nozaki Y, Nakamichi N, Sakakibara H. Varenicline is more effective in attenuating weight gain than nicotine patch 12 months after the end of smoking cessation therapy: an observational study in Japan. Nicotine Tob Res 2014; 16:1026-9. [PMID: 24706051 DOI: 10.1093/ntr/ntu045] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
INTRODUCTION Although both varenicline and nicotine patch have a beneficial effect in controlling postcessation weight gain, it is not well known whether there is a difference in the effect. METHODS We conducted a multi-institutional study on smoking cessation therapy (SCT) administered at 4 Japanese hospitals to compare the body weight change from the first session to 12 months after the end of SCT (at 60 weeks) between varenicline users (n = 307) and nicotine patch users (n = 45). RESULTS The mean weight change from baseline to 12 months after the end of SCT was +0.94 kg (SD: 3.59) in varenicline users and +2.78 kg (SD: 4.88) in nicotine patch users (p = .003, by t test). In multivariate linear regression analysis, varenicline users gained significantly less weight than nicotine patch users (coefficient: -1.787, 95% CI = -2.98 to -0.59) with adjustment for success of quit smoking, age, sex, presence of comorbidity, body mass index at baseline, Fagerström Test for Nicotine Dependence, craving at the end of SCT, and nausea through the SCT. CONCLUSION Our results indicated that varenicline is more effective in attenuating weight gain than nicotine patch in smokers who received Japanese SCT.
Collapse
Affiliation(s)
- Chie Taniguchi
- Department of Nursing, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan; Department of Nursing and Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan;
| | - Hideo Tanaka
- Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan
| | - Noriko Nakamura
- Department of Nursing, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan
| | - Hideo Saka
- Department of Respiratory Medicine and Medical Oncology, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan
| | - Isao Oze
- Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan
| | - Hidemi Ito
- Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan
| | - Kazunobu Tachibana
- Department of Psychosomatic Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan
| | - Akihiro Tokoro
- Department of Psychosomatic Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan
| | - Yasuhiro Nozaki
- Department of Respiratory Medicine, Social Insurance Chukyo Hospital, Nagoya, Aichi, Japan
| | - Nobuyo Nakamichi
- Department of Nursing, Social Insurance Chukyo Hospital, Nagoya, Aichi, Japan
| | - Hisataka Sakakibara
- Department of Nursing and Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
| |
Collapse
|
27
|
Nozaki Y, Kinoshita K, Yano T, Shiga T, Hino S, Niki K, Kishimoto K, Funauchi M, Matsumura I. Estimation of kidney injury molecule-1 (Kim-1) in patients with lupus nephritis. Lupus 2014; 23:769-77. [DOI: 10.1177/0961203314526292] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2013] [Accepted: 02/04/2014] [Indexed: 02/01/2023]
Abstract
Objective Biomarkers of disease activity in lupus nephritis (LN) are needed. Ideally, such biomarkers would be capable of detecting early sub-clinical disease and could be used to gauge response to therapy, thus obviating the need for serial renal biopsies. Much of the focus in the search for LN biomarkers has been on the measurement of urinary chemokines and cytokines in LN patients. However, these have yet to be widely implemented in clinical practice. Kidney injury molecule-1 (Kim-1) is expressed in damaged tubules, but whether urinary (u) and tubular (t)-Kim-1 could serve as a biomarker of active LN is unknown. To investigate the disease activity and histological findings in LN, we evaluated u-Kim-1 levels and t-Kim-1 cells in patients with systemic lupus erythematosus (SLE). Method We measured u-Kim-1 levels and stained t-Kim-1 expression in 57 patients with LN using an ELISA and immunohistochemistry staining. Patients were classified into two groups (active LN, n = 37; inactive LN, n = 20) based on the presence of active renal disease according to the renal SLE disease activity index. correlations of clinical, laboratory data, and histological findings with urinary and t-Kim-1 expression were assessed. Result The u-Kim-1 levels were significantly correlated with the expression of t-Kim-1 ( R = 0.64; P = 0.004) in the SLE patients. The active LN patients exhibited elevated u-Kim-1 levels compared to the inactive LN patients. The number of t-Kim-1 cells was also correlated with histological findings (both glomerular and interstitial inflammation). The u-Kim-1 levels were also correlated with proteinuria and tubular damage in the active LN group. The number of t-Kim-1 cells at baseline was significantly correlated with the estimated glomerular filtration rate ( R = 0.72; P = 0.005) and serum creatinine ( R = 0.53; P = 0.005) after 6–8 months of treatment. Conclusion These data suggest the potential use of the u-Kim-1 levels to screen for active LN and for the estimation of t-Kim-1 expression in renal biopsies to predict renal damage, ongoing glomerular nephritis and tubulointerstitial inflammation, and tubular atrophy.
Collapse
Affiliation(s)
- Y Nozaki
- Department of Hematology and Rheumatology, Kinki University School of Medicine, Osaka, Japan
| | - K Kinoshita
- Department of Hematology and Rheumatology, Kinki University School of Medicine, Osaka, Japan
| | - T Yano
- Department of Hematology and Rheumatology, Kinki University School of Medicine, Osaka, Japan
| | - T Shiga
- Department of Hematology and Rheumatology, Kinki University School of Medicine, Osaka, Japan
| | - S Hino
- Department of Hematology and Rheumatology, Kinki University School of Medicine, Osaka, Japan
| | - K Niki
- Department of Hematology and Rheumatology, Kinki University School of Medicine, Osaka, Japan
| | - K Kishimoto
- Department of Hematology and Rheumatology, Kinki University School of Medicine, Osaka, Japan
| | - M Funauchi
- Department of Hematology and Rheumatology, Kinki University School of Medicine, Osaka, Japan
| | - I Matsumura
- Department of Hematology and Rheumatology, Kinki University School of Medicine, Osaka, Japan
| |
Collapse
|
28
|
Umemoto K, Kojima Y, Akiyama J, Nozaki Y, Nagata N, Sakurai T, Yokoi C, Kobayakawa M, Yanase M. Cytomegalovirus Esophagitis During Chemotherapy in Patients with Esophageal Cancer; a Report of Three Cases. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt460.61] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Fujii T, Sekiguchi M, Matsui K, Kitano M, Hashimoto M, Ohmura K, Yamamoto A, Nakahara H, Maeda K, Yokota A, Miki K, Shimmyo N, Kuroiwa T, Murakami K, Ozaki Y, Higami K, Yoshii I, Nozaki Y, Ikawa T, Morita S, Kawahito Y, Nishimoto N, Mimori T, Sano H. AB0334 Very high titer of anti-citrullinated protein antibodies is associated with the achievement of clinical remission by abatacept in biologic-naïve patients with rheumatoid arthritis (the abroad study). Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2656] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Matsutani T, Murakami M, Sekiguchi M, Matsui K, Kitano M, Namiki M, Ohmura K, Imura Y, Fujii T, Kuroiwa T, Nakahara H, Hika S, Maeda K, Nozaki Y, Funauchi M, Murakami K, Ikawa T, Irimajiri S, Nampei A, Azuma T, Sasaki T, Yokota A, Morita S, Kawahito Y, Mimori T, Sano H, Nishimoto N. SAT0101 Abatacept Treatment Suppresses T Cell Activation in Anti-Cyclic Citrullinated Peptide Antibody (ACPA) Positive RA Patients but not in Acpa Negative RA Patients. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
31
|
Murakami M, Matsutani T, Sekiguchi M, Matsui K, Kitano M, Namiki M, Ohmura K, Imura Y, Fujii T, Kuroiwa T, Nakahara H, Higa S, Maeda K, Nozaki Y, Funauchi M, Murakami K, Ikawa T, Irimajiri S, Nampei A, Azuma T, Sasaki T, Yokota A, Morita S, Kawahito Y, Mimori T, Sano H, Nishimoto N. SAT0121 Changes in Cytokine Profiles in Rheumatoid Arthritis Patients During Abatacept Treatment. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.1847] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
32
|
Nagashima M, Mori M, Monden Y, Yamagata T, Nozaki Y, Fukuda T, Sugie H, Momoi M. [A retrospective study of 18 cases of benign infantile seizures with mild gastroenteritis]. No To Hattatsu 2013; 45:62-63. [PMID: 23593749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
|
33
|
Nozaki Y, Nishizawa N, Omoda E, Kataura H, Sakakibara Y. Power scaling of dispersion-managed Er-doped ultrashort pulse fiber laser with single wall carbon nanotubes. Opt Lett 2012; 37:5079-5081. [PMID: 23258011 DOI: 10.1364/ol.37.005079] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
A high-power, passively mode-locked, Er-doped fiber laser with a single wall carbon nanotube polyimide film was demonstrated in dispersion-managed dissipative-soliton mode-locking operation. The average maximum power of 285 mW and a pulse energy of 8.1 nJ are the highest values yet achieved for single-pulse operation in a nanotube fiber laser. A high-power ultrashort pulse of 680 fs was generated by dispersion compensation at a repetition rate of 34.9 MHz. Passive mode-locking was numerically analyzed, and the dynamics and output properties are discussed.
Collapse
Affiliation(s)
- Y Nozaki
- Department of Electrical Engineering and Computer Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan
| | | | | | | | | |
Collapse
|
34
|
Nakamura A, Tajima K, Zolzaya K, Sato K, Inoue R, Yoneda M, Fujita K, Nozaki Y, Kubota KC, Haga H, Kubota N, Nagashima Y, Nakajima A, Maeda S, Kadowaki T, Terauchi Y. Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance. Diabetologia 2012; 55:3382-91. [PMID: 22955994 DOI: 10.1007/s00125-012-2703-1] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2012] [Accepted: 07/27/2012] [Indexed: 12/20/2022]
Abstract
AIMS/HYPOTHESIS Epidemiological studies have revealed that obesity and diabetes mellitus are independent risk factors for the development of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. However, the debate continues on whether insulin resistance as such is directly associated with NASH and liver tumourigenesis. Here, we investigated the incidence of NASH and liver tumourigenesis in Irs1 ( -/- ) mice subjected to a long-term high-fat (HF) diet. Our hypothesis was that hepatic steatosis, rather than insulin resistance may be related to the pathophysiology of these conditions. METHODS Mice (8 weeks old, C57Bl/6J) were given free access to standard chow (SC) or an HF diet. The development of NASH and liver tumourigenesis was evaluated after mice had been on the above-mentioned diets for 60 weeks. Similarly, Irs1 ( -/- ) mice were also subjected to an HF diet for 60 weeks. RESULTS Long-term HF diet loading, which causes obesity and insulin resistance, was sufficient to induce NASH and liver tumourigenesis in the C57Bl/6J mice. Obesity and insulin resistance were reduced by switching mice from the HF diet to SC, which also protected these mice against the development of NASH and liver tumourigenesis. However, compared with wild-type mice fed the HF diet, Irs1 ( -/- ) mice fed the HF diet were dramatically protected against NASH and liver tumourigenesis despite the presence of severe insulin resistance and marked postprandial hyperglycaemia. CONCLUSIONS/INTERPRETATION IRS-1 inhibition might protect against HF diet-induced NASH and liver tumourigenesis, despite the presence of insulin resistance.
Collapse
Affiliation(s)
- A Nakamura
- Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Nozaki Y, Isobe K, Nakashima I, Shimokata K. Tumor-cytotoxicity of nitric-oxide produced from alveolar macrophages directly stimulated with tumor-cells. Int J Oncol 2012; 2:1053-7. [PMID: 21573670 DOI: 10.3892/ijo.2.6.1053] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Macrophages activated by lipopolysaccharide or interferon-gamma have been shown to be cytotoxic to tumor cells by releasing nitric oxide. Here, we report that unstimulated rat alveolar macrophages cultured with certain tumor cells produce nitric oxide and are cytotoxic to these tumor cells. Alveolar macrophages were taken from BUF/Mna rats, which were known to produce spontaneous thymoma, and cultured with syngeneic BUF/Mna-derived thymoma cells. They were killed by syngeneic or allogeneic alveolar macrophages and this killing was partially abolished by addition of N(G)-monomethyl-L-arginine. X-ray irradiated, mitomycin C-treated or membranous fragments of BUF/Mna-derived thymoma cells directly stimulated rat alveolar macrophages to produce nitric oxide.
Collapse
Affiliation(s)
- Y Nozaki
- NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,NAGOYA,AICHI 466,JAPAN. NAGOYA UNIV,SCH MED,DEPT IMMUNOL,NAGOYA,AICHI 466,JAPAN
| | | | | | | |
Collapse
|
36
|
Nishizawa N, Nozaki Y, Itoga E, Kataura H, Sakakibara Y. Dispersion-managed, high-power, Er-doped ultrashort-pulse fiber laser using carbon-nanotube polyimide film. Opt Express 2011; 19:21874-21879. [PMID: 22109039 DOI: 10.1364/oe.19.021874] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
We investigated a dispersion-managed, passively mode-locked, ultrashort-pulse, Er-doped fiber laser using a polyimide film containing dispersed single-wall carbon nanotubes (SWNTs) and examined the dependence on net cavity dispersion and output coupling ratio using normal-dispersion fibers and a variable output coupler. For the dissipative soliton mode-locking condition, we achieved a pulse energy of 3.5 nJ and an average power of 114 mW, the highest values yet reported for an SWNT fiber laser under single-pulse operation.
Collapse
Affiliation(s)
- N Nishizawa
- Dept. of Electrical Engineering and Computer Science, Nagoya University, Nagoya 464-8603, Japan.
| | | | | | | | | |
Collapse
|
37
|
Takahashi T, Nozaki Y, Nakagawa-Mizuyachi K, Nakayama H, Kawashima M. Changes in angiotensin II receptor bindings in the hen neurohypophysis before and after oviposition. Poult Sci 2011; 90:2565-72. [PMID: 22010242 DOI: 10.3382/ps.2010-01328] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The present study was performed to elucidate whether the angiotensin II (ANG II) receptor exists in the plasma membrane fraction of the neurohypophysis in hens, to estimate the time of action of ANG II on the neurohypophysis before and after oviposition, and to examine relationships between the action of ANG II on the neurohypophysis and those of estrogen and prostaglandin F(2α) (PGF(2α)) in relation to arginine vasotocin (AVT) release. The specific binding had a binding specificity to chicken ANG II (cANG II), reversibility, and saturation in the [(125)I]cANG II binding assay. Scatchard analysis revealed that the binding sites are of a single class. The equilibrium dissociation constant (K(d)) obtained by kinetic analysis and Scatchard analysis suggested a high affinity, and the maximum binding capacity (B(max)) obtained by Scatchard analysis suggested a limited capacity. These results suggest that an ANG II receptor exists in the neurohypophysis of hens. The K(d) and the B(max) value was significantly smaller in laying hens than in nonlaying hens, which suggests that bindings of the cANG II receptor change, depending on the difference in laying condition. Values of the K(d) and the B(max) decreased approximately 15 min before oviposition in laying hens, and decreased 1 h after an intramuscular injection of estradiol-17β and 5 min after an intravenous injection of cANG II in nonlaying hens. The amount of specific binding of PGF(2α) receptor in the neurohypophysis also decreased and AVT concentration in blood increased after the cANG II injection. It seems likely that the action of cANG II in the neurohypophysis increases due to the effect of estrogen approximately 15 min before oviposition, and the cANG II action stimulates AVT release through the increase in the PGF(2α) action in this tissue.
Collapse
Affiliation(s)
- T Takahashi
- Department of Avian Endocrinology, Gifu University, Yanagido, Gifu, Japan
| | | | | | | | | |
Collapse
|
38
|
Mawatari H, Yoneda M, Fujita K, Nozaki Y, Shinohara Y, Sasaki H, Iida H, Takahashi H, Inamori M, Abe Y, Kobayashi N, Kubota K, Kirikoshi H, Nakajima A, Saito S. Association between phospholipids and free cholesterol in high-density lipoprotein and the response to hepatitis C treatment in Japanese with genotype 1b. J Viral Hepat 2010; 17:859-65. [PMID: 20070501 DOI: 10.1111/j.1365-2893.2009.01253.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Pegylated interferon and ribavirin combination therapy is the standard treatment for patients with chronic hepatitis C (CHC), but treatment failure can be difficult to predict. We and others have reported a relation between lipid values and sustained viral responses in patients with CHC. However, the relationship between lipid values and treatment failure has not been previously reported. The present study investigated the association between the profiles of phospholipids and free cholesterol (FC), the main constitutive ingredients of the surface of lipoprotein, classified according to particle size and hepatitis C treatment, and determined the usefulness of these parameters for predicting the outcome of treatment. Fifty-five patients with CHC (33 men and 22 women) were included in the study. The serum total cholesterol, triglyceride, phospholipids, and FC levels in the lipoprotein subclasses were determined using high-performance liquid chromatography with gel permeation columns, enabling the lipoproteins to be classified into 13 subclasses according to particle size. According to a univariate analysis, the treatment failure group had a significantly higher serum phospholipid level overall in the high-density lipoprotein (HDL) and medium HDL fractions as well as a higher serum FC level in the HDL fraction and all HDL subclass fractions compared with the corresponding values in the non-nonvirological response group. Higher serum phospholipid and FC concentrations in the HDL subclasses were predictive of a failure to respond in patients with genotype 1b.
Collapse
Affiliation(s)
- H Mawatari
- Gastroenterology Division, Yokohama City University School of Medicine, Fukuura, Kanazawa-ku, Yokohama City, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Yoneda K, Takahashi H, Abe Y, Inamori M, Kato S, Uchiyama T, Iida H, Mawatari H, Hosono K, Endo H, Nozaki Y, Akiyama T, Fujita K, Yoneda M, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A. A mucosa-associated lymphoid tissue (MALT) lymphoma of the small intestine that was difficult to diagnose endoscopically. Endoscopy 2010; 42 Suppl 2:E175. [PMID: 20560120 DOI: 10.1055/s-0029-1214857] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- K Yoneda
- Gastroenterology Division, Yokohama City University School of Medicine, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Mawatari H, Yoneda M, Fujita K, Nozaki Y, Shinohara Y, Sasaki H, Iida H, Takahashi H, Inamori M, Abe Y, Kobayashi N, Kubota K, Kirikoshi H, Nakajima A, Saito S. Association between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1b. J Viral Hepat 2010; 17:274-9. [PMID: 19708862 DOI: 10.1111/j.1365-2893.2009.01179.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Pegylated interferon and ribavirin combination therapy is the standard treatment for patients with chronic hepatitis C (CHC). Some groups have reported a relation between lipid values and response while others have reported that microsomal triglyceride transfer protein, a key enzyme in the assembly and secretion of lipoproteins, was related to hepatitis C virus (HCV). The aim of this study was to investigate the association between the lipoprotein profiles, classified according to size, and hepatitis C treatment and the usefulness for predicting the outcome of treatment. Forty-four patients with CHC (27 men and 17 women) were included in the study. The serum cholesterol and triglyceride (TG) levels in the lipoprotein subclasses were determined using high-performance liquid chromatography with gel permeation columns, which classified lipoproteins into 20 subfractions based on particle size. According to a univariate analysis, those who achieved an sustained viral response (SVR) had a significantly higher serum total cholesterol level, higher cholesterol levels in the low-density lipoprotein subfraction (25.5 nm in diameter) and the very low-density lipoprotein (VLDL) subfraction (44.5 and 36.8 nm), and a higher serum TG level in the VLDL subfraction (44.5 nm), compared with the corresponding values in the non-SVR group. Higher serum cholesterol and TG concentrations in the lipoprotein subfractions were predictive of an SVR to therapy for HCV infection with genotype 1b prior to the start of interferon treatment.
Collapse
Affiliation(s)
- H Mawatari
- Gastroenterology Division, Yokohama City University School of Medicine, Yokohama, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Endo H, Hosono K, Fujisawa T, Takahashi H, Sugiyama M, Yoneda K, Nozaki Y, Fujita K, Yoneda M, Inamori M, Wada K, Nakagama H, Nakajima A. Involvement of JNK pathway in the promotion of the early stage of colorectal carcinogenesis under high-fat dietary conditions. Gut 2009; 58:1637-43. [PMID: 19570763 DOI: 10.1136/gut.2009.183624] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND AND AIMS The molecular mechanisms underlying the promotion of colorectal carcinogenesis by a high-fat diet (HFD) remain unclear. We investigated the role of the insulin-signal pathway and the c-Jun N-terminal kinase (JNK) pathway, which reportedly play crucial roles in insulin resistance, during colorectal carcinogenesis in the presence of hyperinsulinaemia induced by a HFD. METHODS Azoxymethane-induced aberrant crypt foci formation and cell proliferation in the colonic epithelium were compared between mice fed a normal diet (ND) and mice fed a HFD. A western blot analysis was performed to elucidate the mechanism affecting colorectal carcinogenesis by a HFD. RESULTS The number of aberrant crypt foci and the colonic epithelial cell proliferative activity were significantly higher in the HFD group than in the ND group. While the plasma insulin level was significantly higher in the HFD group than in the ND group, a western blot analysis revealed the inactivation of Akt, which is located downstream of the insulin receptor, in the colonic epithelia of the HFD group. On the other hand, JNK activity was significantly higher in the HFD group than in the ND group. A JNK specific inhibitor significantly suppressed the increase in epithelial cell proliferation only under a HFD, but not under a ND. CONCLUSIONS Colonic cell proliferation was promoted via the JNK pathway in the presence of a HFD but not in the presence of a ND. This novel mechanism may explain the involvement of the JNK pathway in the effect of dietary fat intake on colon carcinogenesis.
Collapse
Affiliation(s)
- H Endo
- 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan;
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Yoshimoto T, Hisada A, Hasegawa T, Nozaki Y, Matoba M. [Efficacy and safety of continuous subcutaneous injection of the compound oxycodone in cancer pain management: the first 4-year audit]. Gan To Kagaku Ryoho 2009; 36:1683-1689. [PMID: 19838028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The compound oxycodone injection, but not pure oxycodone, has been available since the 1920's in Japan. The compound, containing oxycodone and hydrocotarnine, can be subcutaneously administered. Hydrocotarnine is a non-narcotic opium alkaloid. Nowadays, along with the increase in the prescription frequency of oral oxycodone, the compound oxycodone injection is regarded as an important alternative in palliative care. However, few clinical reports about this drug have been documented in Japan. We have intensively introduced the compound for cancer pain control since 4 years ago and we report a study on the safety and efficacy of the continuous subcutaneous administration of the compound injection. Ninety-seven patients were naively administered the compound for cancer pain control and the mean administered period was 18. 0+/-15. 5 days. 61. 9% of all cases were switched from oral oxycodone. The efficacy in cancer pain control was evaluated for the first two weeks using a numeric rating scale (NRS: 0, no pain, and 10, imaginary worst ). They had statically shown pain control improvement from 6. 8+/-2. 8 on administration to 2. 4+/-2. 5 one week later, 1. 7+/-1. 9 two weeks later, and 2. 3 +/-2. 6 on the last observation day of the study (p<0. 001). One week later on administration, no significant adverse effects were found in the serology, conscious level, and subjective symptoms of nausea and vomiting. But adverse effects difficult to manage were experienced in 7. 2%, including delirium, constipation, nausea and vomiting, vertigo, and local skin toxicity on the injected site. All episodes were experienced within 16 days of compound administration, which had been followed by switching to fentanyl or subcutaneous morphine injection. The conversion ratio from compound oxycodone injection to oral oxycodone was 1. 43 without adjustment required(n=35). We speculate that the compound can be regarded as a pure oxycodone injection using continuous subcutaneous administration. While our clinical audit is a primitive one, we may conclude that the continuous subcutaneous administration of the compound oxycodone injection should be effective and safe in clinical use for cancer pain control.
Collapse
|
43
|
Akiyama T, Inamori M, Akimoto K, Iida H, Mawatari H, Endo H, Ikeda T, Nozaki Y, Yoneda K, Sakamoto Y, Fujita K, Yoneda M, Takahashi H, Hirokawa S, Goto A, Abe Y, Kirikoshi H, Kobayashi N, Kubota K, Saito S, Nakajima A. Risk factors for the progression of endoscopic Barrett's epithelium in Japan: a multivariate analysis based on the Prague C & M Criteria. Dig Dis Sci 2009; 54:1702-7. [PMID: 19003532 DOI: 10.1007/s10620-008-0537-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2007] [Accepted: 09/11/2008] [Indexed: 01/10/2023]
Abstract
PURPOSE To determine the prevalence and progression of Barrett's epithelium and associated risk factors in Japan. METHODS The study population comprised 869 cases. Endoscopic Barrett's epithelium was diagnosed based on the Prague C & M Criteria. The correlations of clinical factors with the prevalence and progression of endoscopic Barrett's epithelium were examined. RESULTS Endoscopic Barrett's epithelium was diagnosed in 374 cases (43%), in the majority of which the diagnosis was short-segment Barrett's esophagus. The progression of Barrett's epithelium was identified in 47 cases. In univariate and multiple logistic regression analyses, aging, smoking habit, and erosive esophagitis were significantly associated with the prevalence of Barrett's epithelium, whereas aging and erosive esophagitis, especially severe erosive esophagitis, were significant contributing factors to the progression of Barrett's epithelium. CONCLUSIONS Forty-three percent of the total study population was diagnosed as having endoscopic Barrett's epithelium. During the follow-up period, 12.6% of the cases with Barrett's epithelium exhibited progression which was associated with aging and severe erosive esophagitis.
Collapse
Affiliation(s)
- T Akiyama
- Division of Gastroenterology, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Sugiyama M, Funauchi M, Yamagata T, Nozaki Y, Yoo BS, Ikoma S, Kinoshita K, Kanamaru A. Predominant inhibition of Th1 cytokines in New Zealand black/white F1 mice treated with FK506. Scand J Rheumatol 2009; 33:108-14. [PMID: 15163112 DOI: 10.1080/03009740310004351] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The T-helper 1/T-helper 2 (Th1/Th2) cell balance was examined in 6-month-old New Zealand black/white F1 (B/WF1) mice treated with an immunosuppressive agent, FK506. The survival rate of mice treated with 10 mg/kg/day of FK506 was 7/8, while that of those treated with 2.5 mg/kg/day was 5/8, and 4/8 after treatment for 8 weeks with placebo. Proteinuria, which was already positive in all mice before the treatment, in the seven of eight mice treated with 10 mg/kg/day remained mildly positive (< or = 1+), while seven of eight mice treated with 2.5 mg/kg/day and six of eight mice treated with the placebo showed severe proteinuria (> or = 2+). Pathological changes in the kidneys of mice treated with 10 mg/kg/day of FK506 were less severe than in mice treated with the placebo or 2.5 mg/kg/day of FK506. Expression of mRNA was unchanged for all cytokines determined in the groups treated with 2.5 mg/kg/day of FK506 or placebo. In contrast, expression of mRNA for interleukin (IL)-2, and interferon (IFN)-gamma was suppressed, while that for IL-4 and IL-10 was not suppressed in the group treated with 10 mg/kg of FK506. The serum levels of IgG-class anti-DNA antibodies, which had been elevated before the treatment, were suppressed--especially in the IgG2a subclass--and the deposition of IgG2a and IgG2b in the glomeruli was reduced in the group treated with 10 mg/kg/day of FK506 compared with the other groups. These findings suggest that an improvement in the lupus nephritis of 6-month-old B/WF1 mice induced by FK506 might be associated with a predominant inhibition of Th1 cytokine.
Collapse
Affiliation(s)
- M Sugiyama
- Division of Haematology, Nephrology, and Rheumatology, Kinki University School of Medicine, Osaka, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Abe Y, Inamori M, Uchiyama T, Iida H, Akimoto K, Mawatari H, Nozaki Y, Hosono K, Endo H, Akiyama T, Yoneda K, Fujita K, Yoneda M, Takahashi H, Goto A, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A. Education and imaging. Gastrointestinal: Aneurysmal artery in a gastric ulcer after endoscopic hemostasis. J Gastroenterol Hepatol 2009; 24:323. [PMID: 19215338 DOI: 10.1111/j.1440-1746.2008.05765.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Affiliation(s)
- Y Abe
- Gastroenterology Division, Yokohama City University School of Medicine, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Fujita K, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, Iwasaki T, Inamori M, Abe Y, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nagashima Y, Nakajima A. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut 2008; 57:1583-91. [PMID: 18596193 DOI: 10.1136/gut.2007.144550] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
OBJECTIVE No effective drugs have been developed to date to prevent or treat non-alcoholic fatty liver disease (NAFLD), although diet modification and exercise to improve obesity have been attempted. Therefore, development of a novel drug/strategy to treat NAFLD is urgently needed. In the present study, a novel concept is proposed for the treatment of NAFLD. METHODS Fisher 344 male rats were given a choline-deficient, l-amino acid-defined (CDAA) diet or a high-fat high-calorie (HF/HC) diet with or without the antiplatelet agents, aspirin, ticlopidine or cilostazol for 16 weeks. Liver steatosis, inflammation and fibrosis, and the possible mechanisms involved were investigated. RESULTS All three antiplatelet drugs, namely aspirin, ticlopidine and cilostazol, significantly attenuated liver steatosis, inflammation and fibrosis in the CDAA diet group. Of the three agents, cilostazol was the most effective, and the drug also suppressed HF/HC diet-induced liver steatosis. Cilostazol appeared to exert its beneficial effect against NAFLD by suppressing mitogen-activated protein kinase activation induced by oxidative stress and platelet-derived growth factor via intercepting signal transduction from Akt to c-Raf. CONCLUSION Antiplatelet agents, especially cilostazol, offer the promise of becoming key agents for the treatment of NAFLD.
Collapse
Affiliation(s)
- K Fujita
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236-0004, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Nozaki Y, Kakumoto M, Ohta M, Yukimatsu K, Chien YW. A New Transmucosal Therapeutic System: Overview of Formulation Development and in Vitro/In Vivo Clinical Performance. Drug Dev Ind Pharm 2008. [DOI: 10.3109/03639049309038767] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
48
|
Yukimatsu K, Nozaki Y, Kakumoto M, Ohta M. Development of a Trans-Mucosal Controlled-Release Device for Systemic Delivery of Antianginal Drugs Pharmacokinetics and Pharmacodynamics. Drug Dev Ind Pharm 2008. [DOI: 10.3109/03639049409038315] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
49
|
Nozaki Y, Kakumoto M, Ohta M, Yukimatsu K, Chien YW. A New Transmucosal Therapeutic System: Overview of Formulation Development and in Vitro/in Vivo Clinical Performance. Drug Dev Ind Pharm 2008. [DOI: 10.3109/03639049309050167] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
50
|
Yoneda M, Saito S, Ikeda T, Fujita K, Mawatari H, Kirikoshi H, Inamori M, Nozaki Y, Akiyama T, Takahashi H, Abe Y, Kubota K, Iwasaki T, Terauchi Y, Togo S, Nakajima A. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat 2007; 14:600-7. [PMID: 17697011 DOI: 10.1111/j.1365-2893.2006.00836.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Insulin resistance (IR) is known to be associated with the visceral adipose tissue area. Elucidation of the relationship between hepatitis C virus (HCV) and IR is of great clinical relevance, because IR promotes liver fibrosis. In this study, we tested the hypothesis that HCV infection by itself may promote IR. We prospectively evaluated 47 patients with chronic HCV infection who underwent liver biopsy. Patients with obesity, type 2 diabetes mellitus (DM), or a history of alcohol consumption were excluded. IR was estimated by calculation of the modified homeostasis model of insulin resistance (HOMA-IR) index. Abdominal fat distribution was determined by computed tomography. Fasting blood glucose levels were within normal range in all the patients. The results of univariate analysis revealed a significant correlation between the quantity of HCV-RNA and the HOMA-IR (r = 0.368, P = 0.0291). While a significant correlation between the visceral adipose tissue area and the HOMA-IR was also observed in the 97 control, nondiabetic, non-HCV-infected patients (r = 0.398, P < 0.0001), no such significant correlation between the visceral adipose tissue area and the HOMA-IR (r = 0.124, P = 0.496) was observed in the patients with HCV infection. Multiple regression analysis with adjustment for age, gender and visceral adipose tissue area revealed a significant correlation between the HCV-RNA and the HOMA-IR (P = 0.0446). HCV is directly associated with IR in a dose-dependent manner, independent of the visceral adipose tissue area. This is the first report to demonstrate the direct involvement of HCV and IR in patients with chronic HCV infection.
Collapse
Affiliation(s)
- M Yoneda
- Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|